Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03511040
Other study ID # PR17-006
Secondary ID
Status Recruiting
Phase N/A
First received April 10, 2018
Last updated April 17, 2018
Start date March 14, 2018
Est. completion date December 30, 2018

Study information

Verified date April 2018
Source Neurvana Medical
Contact Nate Knock
Phone +1-949.743.1158
Email nknock@NEURVANAMEDICAL.COM
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The LOVIT study is a European prospective, multi-center, open-label, single-arm feasibility trial designed to determine the safety and angiographic effectiveness through 30 days post treatment with Lumenate Intraluminal Device in the treatment of symptomatic vasospasm.


Description:

The Neurvana Lumenate Intraluminal Device is delivered via a percutaneous endovascular approach to the target segment for mechanical assistance and the treatment of vasospasm.

The LOVIT study is a European prospective, multi-center, open-label, single-arm feasibility trial designed to determine the safety and angiographic effectiveness through 30 days post treatment with Lumenate Intraluminal Device in the treatment of symptomatic vasospasm. The primary objective of the study is to support the CE-mark vasospasm label claim for the Lumenate Device. The study will be enrolled at up to 8 European sites with study subjects being followed for 90 days post-treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 30, 2018
Est. primary completion date October 30, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age = 18

2. Subject has the necessary mental capacity to participate and is willing and able to comply with protocol requirements

3. Patient has suffered SAH from a ruptured intracranial aneurysm

4. Has mWFNS =3 upon admission to the treating hospital or mWFNS =3 after insertion of an endoventricular drain (EVD) for acute hydrocephalus secondary to SAH.

5. Subject has provided written informed consent using the IRB/Ethics committee-approved consent form and are willing to comply with the study protocol and planned follow-ups.

6. Patients that develop symptoms of cerebral vasospasm, as determined by the physician, and/or have diagnostic (e.g. TCD) or radiological evidence of moderate/severe vasospasm.

Exclusion Criteria:

1. Patients that have angiographically confirmed (CTA/MRA) vasospasm at admission to the treating hospital

2. Subjects who require surgical treatment of culprit aneurysm.

3. Endovascular treatment of culprit aneurysm resulting in severe procedural complication (e.g., vessel rupture, embolization or other complication).

4. Placement of intraluminal stent or flow diverter is used to treat culprit aneurysm.

5. Intraluminal stent or flow diverter placed in the 6 months prior to culprit aneurysm rupture.

6. Treated with Intra Arterial vasodilators prior to Lumenate procedure

7. Receiving Anti-coagulant with half-life longer than 24 hours, or Dual antiplatelet therapy (DAPT) including P2Y12 inhibition

8. Woman of child-bearing potential who cannot provide a negative pregnancy test.

9. Patients with vasculitis or connective tissue disorders that put them at risk for vasculitis.

10. Known use of cocaine or methamphetamine within the last month.

11. Any comorbid disease or medical condition with a life expectancy =3 months.

12. Known allergy or contraindication to aspirin, heparin, local or general anesthesia

13. Known history of life threatening allergy to contrast dye

14. Serum creatinine =2.5 mg/dL

15. Enrollment in another trial involving an investigational product

16. Physician discretion that the patient may not benefit from treatment with Lumenate - reason for exclusion should be documented.

Study Design


Intervention

Device:
Lumenate Intraluminal Device
Dilation of vasospastic intracranial vessels

Locations

Country Name City State
France Foundation Adolphe de Rothschild Paris
France Hospital Purpan Toulouse
Germany Uniklinik RWTH Aachen Aachen
Hungary National Institute of Neurosciences Budapest
Sweden Karolinska Universitetssjukhuset Stockholm Solna

Sponsors (1)

Lead Sponsor Collaborator
Neurvana Medical

Countries where clinical trial is conducted

France,  Germany,  Hungary,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Vasospasm treatment freedom from complication (Primary Safety Endpoint) No occurrence of device-related procedural complications as assessed by the post treatment angiogram. Catheter angiography will be used to determine the absence/presence of vessel wall disruption (e.g., dissection, perforation) or presence of thrombus within the target vessel. Acute - immediate post-procedure
Secondary Vessel caliber change post procedure (Secondary Effectiveness Endpoint) The study's primary effectiveness endpoint is an improvement in the caliber of the treated vasospastic vessel by at least 1 point on the 4-point angiographic scale Acute - immediate post-procedure
Secondary Freedom from device-related SAEs at 30 days (Secondary Descriptive Endpoint) Any device-related serious adverse events at 30±5 days post-treatment 30±5 days post-procedure
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Recruiting NCT04189471 - Recovery After Cerebral Hemorrhage
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Completed NCT05131295 - Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage. Phase 3
Recruiting NCT02962349 - TRansfusion Strategies in Acute Brain INjured Patients N/A
Completed NCT02872857 - Subarachnoid Hemorrhage Recovery And Galantamine Phase 1/Phase 2
Completed NCT03164434 - Influence of Drainage on EVD ICP-signal
Terminated NCT02216513 - Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage Phase 0
Not yet recruiting NCT00905931 - Lycopene Following Aneurysmal Subarachnoid Haemorrhage Phase 2
Completed NCT02389634 - Identification of Novel Molecular Markers for Vasospasm
Completed NCT01077206 - High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage Phase 2/Phase 3
Completed NCT00962546 - Computed Tomographic (CT) Perfusion and CT Angiography as Screening Tools for Vasospasm Following Subarachnoid Hemorrhage N/A
Completed NCT01261091 - Early Tracheostomy in Ventilated Stroke Patients N/A
Completed NCT00507104 - Pituitary Functions After Traumatic Brain Injury (TBI) and/or Subarachnoid Hemorrhage (SAH)
Completed NCT00071565 - Familial Intracranial Aneurysm Study II N/A
Recruiting NCT05113381 - The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of IVH N/A
Completed NCT04052646 - Prehospital Deaths From Spontaneous Subarachnoid Haemorrhages
Recruiting NCT04548596 - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Recruiting NCT06033378 - Blood Pressure Treatment in ICU Patients With Subarachniodal Haemorrhage. N/A
Completed NCT04308577 - Diet Induced Ketosis for Brain Injury - A Feasibility Study N/A